Loading...
Loading...
India's ramipril imports from BULGARIA total $849 across 8 shipments from 1 foreign suppliers. BALKANPHARMA-DUPNITSA AD leads with $849 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for ramipril โ a concentrated sourcing relationship with select suppliers from BULGARIA.

BALKANPHARMA-DUPNITSA AD is the leading Ramipril supplier from BULGARIA to India, with import value of $849 across 8 shipments. The top 5 suppliers โ BALKANPHARMA-DUPNITSA AD โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | BALKANPHARMA-DUPNITSA AD | $849 | 8 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED | $849 | 8 | 100.0% |
BULGARIA โ India trade corridor intelligence
The Bulgaria to India trade corridor for finished pharmaceutical formulations containing Ramipril is currently stable. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra is minimal, facilitating efficient logistics. Freight rates are competitive, and the exchange rate between the Indian Rupee (INR) and the Bulgarian Lev (BGN) remains favorable for trade. These factors contribute to a conducive environment for the import of Ramipril formulations from Bulgaria to India.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While this initiative encourages local production, it does not directly impact the import of finished pharmaceutical formulations containing Ramipril from Bulgaria, as the PLI scheme primarily targets domestic manufacturers. Import substitution policies may influence future import patterns, but currently, the demand for specialized Ramipril formulations continues to drive imports from Bulgaria.
India and Bulgaria maintain a cordial trade relationship, with ongoing discussions to enhance bilateral trade, including in the pharmaceutical sector. There are no specific Free Trade Agreements (FTAs) between the two countries, but both nations are members of the World Trade Organization (WTO), which facilitates trade. Mutual recognition of Good Manufacturing Practices (GMP) and other regulatory standards is under consideration to streamline pharmaceutical trade.
The landed cost for importing finished Ramipril formulations from Bulgaria to India includes the following components:
Per-unit estimates can be calculated by dividing the total landed cost by the number of units in the shipment.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Ramipril into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 41 for registration and Form 10 for the import license. The manufacturer must also provide a valid manufacturing or wholesale license from their country of origin. The registration certificate is valid for three years and can be renewed by applying nine months before its expiry. The import license is also valid for three years and is renewable under similar conditions. The application process typically takes several months, depending on the completeness of the submitted documentation and the CDSCO's processing times.
Imported finished pharmaceutical formulations containing Ramipril must undergo quality testing at a CDSCO-approved laboratory in India. The manufacturer is required to submit samples from each batch for testing, along with the Certificate of Analysis (CoA) from the exporting country's laboratory. The CoA should include details such as method of analysis, impurity standards, and reference standards. Stability data, particularly for ICH Zone IV conditions, should also be provided. The testing process ensures that the imported formulations meet the standards set by the Indian Pharmacopoeia. Port inspection by customs drug inspectors is conducted to verify compliance with regulatory requirements.
In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported drugs, including finished formulations containing Ramipril. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations stipulate that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution. Additionally, for unapproved and approved new drugs manufactured in SEZs, the requirements specified for manufacturing of new drugs under NDCT Rules 2019 and Drug Rules 1945 must be complied with.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Ramipril formulations to meet the demand for antihypertensive treatments, particularly for patented or branded formulations and specific dosage forms not produced domestically. The domestic pharmaceutical industry may lack the capacity to manufacture certain specialized Ramipril formulations, leading to reliance on imports. The market size for Ramipril formulations in India is substantial, with a growing patient population requiring effective hypertension management.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations containing Ramipril under HS Code 30049071 is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is levied at 10% of the BCD, and the Integrated Goods and Services Tax (IGST) is applicable at 12%. There are no anti-dumping duties or exemptions for this product category. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.
India sources finished Ramipril formulations from Bulgaria due to the competitive advantages offered by Bulgarian manufacturers, such as patents, specialized dosage forms, and adherence to quality standards. Bulgaria's share in the Indian market for Ramipril formulations is notable, with the top supplier being BALKANPHARMA-DUPNITSA AD. Other suppliers include countries like China, Germany, and the United States, but Bulgaria's unique advantages make it a preferred source for certain formulations.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Ramipril formulations from Bulgaria due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. Bulgaria's adherence to international quality standards and competitive pricing further make it an attractive sourcing destination for Indian pharmaceutical companies.
Compared to other origins like China, Germany, and the United States, Bulgaria offers competitive pricing, high-quality products, and reliable delivery schedules. While China may offer lower prices, concerns about quality and regulatory compliance can be a drawback. Germany and the United States provide high-quality products but at higher prices. Bulgaria's unique advantage lies in its balance of quality and cost-effectiveness, making it a preferred choice for certain Ramipril formulations.
Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring regulatory developments in both India and Bulgaria is crucial to anticipate and adapt to any changes that may impact the supply chain.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Ramipril suppliers from BULGARIA to India include BALKANPHARMA-DUPNITSA AD. The leading supplier is BALKANPHARMA-DUPNITSA AD with import value of $849 USD across 8 shipments. India imported Ramipril worth $849 USD from BULGARIA in total across 8 shipments.
India imported Ramipril worth $849 USD from BULGARIA across 8 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Ramipril sourced from BULGARIA include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED. The largest buyer is ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED with $849 in imports across 8 shipments.
The total value of Ramipril imports from BULGARIA to India is $849 USD, across 8 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
8 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists